profit from every $100 of sales.
$0$100
Ironwood Pharmaceuticals
$4.68+6.61% today
+143.8% in 1 year
1-year low $1.921-year high $5.39
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $32.26 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Ironwood Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $411 million in 2022 to $296 million in 2025, with $24.0 million of profit last year.
SalesProfit
Ironwood Pharmaceuticals vs. similar companies
Ironwood Pharmaceuticals grows the slowest of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Ironwood Pharmaceuticals | 32.3× · Expensive | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 88.6× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.6× · Expensive |
AI analysis
An AI analyst reads Ironwood Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 411 | 443 | 351 | 296 | |
| 411 | – | – | – | |
| 250 | 168 | 96 | 119 | |
| 261 | -925 | 100 | 105 | |
| 175 | -1,002 | 1 | 24 | |
| 0.96 | -6.45 | 0.01 | 0.15 | |
| 100.0% | – | – | – | |
| 61.0% | 38.0% | 27.2% | 40.1% | |
| 42.6% | -226.4% | 0.3% | 8.1% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,101 | 471 | 351 | 397 |
| Cash | 656 | 92 | 89 | 215 |
| Total debt | 416 | 716 | 599 | 598 |
| Total liabilities | 448 | 817 | 652 | 659 |
| 652 | -346 | -301 | -262 | |
| 186 | 155 | 160 | 163 | |
| 19.2% | -198.2% | 26.0% | 24.2% | |
| 26.8% | 289.4% | -0.3% | -9.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 274 | 183 | 104 | 127 | |
| 0 | 0 | 0 | 0 | |
| 274 | 183 | 103 | 127 | |
| Dividends paid | – | – | – | – |
| 126 | 0 | 0 | – | |
| 27 | 32 | 30 | 17 |
Valuation
- 32.3×
- 3.5×
- –
- -2.2×
- 2.6×
- 6.1×
- 11.1×
- 16.4%
- 3.1%
- 0.0%
Profitability
- 99.8%
- 40.1%
- 8.1%
- 56.8%
- 24.8%
- -33.0%
- -57.4%
- 34.7%
- 100.8%
- 24.8%
Growth
- −10.3%
- −46.1%
- +22.8%
- –
- −4.4%
Financial health
- 3.7×
- -2.28
- 137.5%
- 3.1×
- 1.13
- 1.41
- 0.83
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 5%of 948
Top 4%of 871
Bottom 43%of 560
Bottom 8%of 868
Top 4%of 985
What analysts expect
- Average price target
- $4.80
- Range
- $3.70 – $5.70
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 0.24 | 0.07 | +242.9% |
| Feb 25, 2026 | -0.01 | 0.02 | −150.0% |
| Nov 10, 2025 | 0.24 | 0.09 | +166.7% |
| Aug 7, 2025 | 0.14 | -0.02 | +800.0% |
| May 7, 2025 | -0.14 | -0.05 | −180.0% |
| Feb 27, 2025 | 0.02 | 0.10 | −80.0% |
| Nov 7, 2024 | 0.02 | 0.08 | −75.0% |
| Aug 8, 2024 | -0.01 | 0.15 | −103.6% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
49No pass
Benjamin Graham
25No pass
Philip Fisher
50No pass
Peter Lynch
16No pass
Joel Greenblatt
58No pass
Charlie Munger
58No pass
Terry Smith
54No pass
Questions about Ironwood Pharmaceuticals
Is Ironwood Pharmaceuticals a good stock to buy?
A business with weak numbers, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Ironwood Pharmaceuticals AI analysis
What does Ironwood Pharmaceuticals do?
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It is in Drug Manufacturers - Specialty & Generic.
Does Ironwood Pharmaceuticals pay a dividend?
No. Ironwood Pharmaceuticals does not pay a dividend at the moment.
Is Ironwood Pharmaceuticals stock halal?
No. Ironwood Pharmaceuticals does not pass our halal screen: its debt is 77% of its market value, at or above the 33% limit. How we check
How has Ironwood Pharmaceuticals stock done over the past year?
Up 143.8% over the past twelve months, to $4.68. It traded between $1.92 and $5.39 and is 13.2% below its high.
Who are Ironwood Pharmaceuticals's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Ironwood Pharmaceuticals's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.